文献速递淋巴瘤白血病

全基因组CRISPR筛选鉴定成人T细胞白血病/淋巴瘤中PD-L1表达的分子机制

Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma.
PubMed 文献 · Blood · 2024-01-01

本研究在成人T细胞白血病/淋巴瘤(ATLL)细胞中进行无偏倚全基因组CRISPR筛选,发现NEDD8、NAE1、UBA3和CUL3负向调控PD-L1表达,STAT3正向调控。JAK1/2抑制剂芦可替尼降低PD-L1表达,neddylation通路抑制剂pevonedistat增加PD-L1表达,且这些结果不受PD-L1 3'结构变异影响。Pevonedistat单药对ATLL细胞有细胞毒性,并在体外增强抗PD-L1单抗avelumab和靶向PD-L1的CAR T细胞的细胞毒性作用。

要点

  • 全基因组CRISPR筛选发现NEDD8、NAE1、UBA3、CUL3负向调控PD-L1,STAT3正向调控。
  • 芦可替尼降低ATLL细胞PD-L1表达,pevonedistat增加PD-L1表达。
  • Pevonedistat在体外增强avelumab和PD-L1 CAR T细胞的细胞毒性。

核心结论

  • 本研究揭示了ATLL细胞中PD-L1表达的部分复杂调控机制,并证明利用pevonedistat上调PD-L1可增强PD-L1靶向免疫治疗在体外的初步临床前疗效。

研究设计与样本

  • 在ATLL细胞中进行无偏倚全基因组CRISPR筛选,并开展体外验证实验。

主要发现

  • 在ATLL细胞中,neddylation相关基因NEDD8、NAE1、UBA3和CUL3负向调控PD-L1表达,而STAT3正向调控PD-L1表达。
  • JAK1/2抑制剂芦可替尼处理导致ATLL细胞PD-L1表达降低,neddylation通路抑制剂pevonedistat处理导致PD-L1表达增加。
  • 无论ATLL细胞是否携带PD-L1 3'结构变异,上述结果均成立。
  • Pevonedistat单药对ATLL细胞显示细胞毒性,且与各单药相比,pevonedistat在体外增强抗PD-L1单克隆抗体avelumab和靶向PD-L1的嵌合抗原受体(CAR)T细胞的细胞毒性作用。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adult T-cell leukemia/lymphoma (ATLL) is an aggressive T-cell malignancy with a poor prognosis and limited treatment options. Programmed cell death ligand 1(PD-L1) is recognized to be involved in the pathobiology of ATLL. However, what molecules control PD-L1 expression and whether genetic or pharmacological intervention might modify PD-L1 expression in ATLL cells are still unknown. To comprehend the regulatory mechanisms of PD-L1 expression in ATLL cells, we performed unbiased genome-wide clustered regularly interspaced short palindromic repeat (CRISPR) screening in this work. In ATLL cells, we discovered that the neddylation-associated genes NEDD8, NAE1, UBA3, and CUL3 negatively regulated PD-L1 expression, whereas STAT3 positively did so. We verified, in line with the genetic results, that treatment with the JAK1/2 inhibitor ruxolitinib or the neddylation pathway inhibitor pevonedistat resulted in a decrease in PD-L1 expression in ATLL cells or an increase in it, respectively. It is significant that these results held true regardless of whether ATLL cells had the PD-L1 3' structural variant, a known genetic anomaly that promotes PD-L1 overexpression in certain patients with primary ATLL. Pevonedistat alone showed cytotoxicity for ATLL cells, but compared with each single modality, pevonedistat improved the cytotoxic effects of the anti-PD-L1 monoclonal antibody avelumab and chimeric antigen receptor (CAR) T cells targeting PD-L1 in vitro. As a result, our work provided insight into a portion of the complex regulatory mechanisms governing PD-L1 expression in ATLL cells and demonstrated the in vitro preliminary preclinical efficacy of PD-L1-directed immunotherapies by using pevonedistat to upregulate PD-L1 in ATLL cells.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Chiba M, Shimono J, Suto K, et al. Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma. Blood. 2024. PMID: 38142436. doi:10.1182/blood.2023021423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。